An open-label, multicentre, randomised, phase III study comparing topotecan/cisplatin and topotecan/etoposide versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive disease-small cell lung cancer

Trial Profile

An open-label, multicentre, randomised, phase III study comparing topotecan/cisplatin and topotecan/etoposide versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive disease-small cell lung cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Topotecan (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Aug 2009 Actual end date (1 Feb 2007) added as reported by ClinicalTrials.gov.
    • 26 Jun 2008 Final results reported at ASCO 2008 (1112884)
    • 17 Jul 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top